Willow Biosciences Inc. (TSX: WLLW) (OTCQB: CANSF) has reached an agreement to sell its wholly-owned operating subsidiary Epimeron USA, Inc. to an unnamed private UK-based company for US$3.38 million in cash, the company announced Friday.
The Alberta-based biotechnology firm said in a statement that the transaction includes the company’s biotechnology business,…
Please login to read all 344 words.
